Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.
Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Positive
- None.
Negative
- None.
News Market Reaction 23 Alerts
On the day this news was published, CBLL gained 7.04%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $33M to the company's valuation, bringing the market cap to $505M at that time. Trading volume was above average at 2.0x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
FAQ
When will Ceribell (CBLL) report Q3 2025 financial results?
What time is the Ceribell (CBLL) conference call on November 4, 2025?
How can investors join the Ceribell (CBLL) Nov. 4, 2025 earnings call by phone?
Will there be a webcast for Ceribell's (CBLL) Q3 2025 results and where is it available?
Is the Ceribell (CBLL) Q3 2025 webcast archived for later listening?
What access code is required to join the Ceribell (CBLL) earnings call on Nov 4, 2025?
